Department of Hematology/Oncology, University of Halle, Ernst-Grube-Str. 40, Halle 06120, Germany.
Department of Hematology/Oncology, University of Halle, Ernst-Grube-Str. 40, Halle 06120, Germany.
Crit Rev Oncol Hematol. 2015 Jun;94(3):279-90. doi: 10.1016/j.critrevonc.2015.02.012. Epub 2015 Mar 6.
Trabectedin is an approved antineoplastic agent for the treatment of adult patients with advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in patients with relapsed platinum sensitive ovarian cancer. The mechanism of action is still not fully understood but many typical side effects seen with other chemotherapy drugs are less common, mild or unreported. Although this apparent favorable safety profile suggests a well-tolerated and manageable therapeutic option in the palliative care setting, trabectedin does have specific adverse side effects which can be hazardous for individual patients. The most commonly observed toxicities with trabectedin include neutropenia, nausea, vomiting, and increases in liver transaminases, anemia, fatigue, thrombocytopenia, anorexia and diarrhea. However, for most patients the appropriate use of supportive care strategies can reduce or overcome these side effects. We present a concise review of the safety data of trabectedin with the corresponding overview of the supportive care strategies.
曲贝替定是一种已批准用于治疗成人晚期软组织肉瘤的抗肿瘤药物，或与聚乙二醇化脂质体阿霉素（PLD）联合用于复发性铂类敏感卵巢癌患者。其作用机制尚不完全清楚，但许多与其他化疗药物相关的典型副作用不太常见、较轻或未报告。尽管这种明显有利的安全性特征表明在姑息治疗环境中是一种耐受良好且可管理的治疗选择，但曲贝替定确实有特定的不良反应，可能对个别患者有危险。曲贝替定最常见的毒性反应包括中性粒细胞减少、恶心、呕吐和肝转氨酶升高、贫血、疲劳、血小板减少、厌食和腹泻。然而，对于大多数患者，适当使用支持性护理策略可以减少或克服这些副作用。我们简要回顾了曲贝替定的安全性数据，并概述了相应的支持性护理策略。
